secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001654954-25-010579
Event type: other
Sentiment:  positive
Materiality: 0.35
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZIVO CEO letter highlights algae antioxidant validation and animal health progress
--------------------------------------------------------------------------------

- Independent analysis showed ZIVO's algae has nearly double SOD activity vs. a competing algae product.
- Poultry avian influenza study: treated birds showed delayed transmission, lower viral shedding, faster immune response.
- Management and board personally invested in the Company, signaling conviction in undervalued stock.
- Company targets $4.5B antibiotic-free feed market growing at 8.2% CAGR through 2033.
- CEO acknowledges liquidity challenges but expects near-term revenue from nutraceutical commitments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495425010579/0001654954-25-010579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495425010579/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-010579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer